Archon Capital Management’s Harvard Bioscience HBIO Stock Holding History

Archon Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,086	Closed	-$1.11M	–	27
2024 Q1	$1.11M	Sell	26,086 -1,850	-7%	-$83.2K	0.38%	32
2023 Q4	$1.49M	Hold	27,936	–	–	0.37%	31
2023 Q3	$1.2M	Hold	27,936	–	–	0.32%	33
2023 Q2	$1.53M	Sell	27,936 -108,241	-79%	-$5.94M	0.32%	30
2023 Q1	$5.72M	Hold	136,177	–	–	1.28%	25
2022 Q4	$3.77M	Buy	136,177 +5,624	+4%	+$139K	1.1%	23
2022 Q3	$3.34M	Buy	130,553 +34,905	+36%	+$1.15M	0.59%	29
2022 Q2	$3.44M	Buy	95,648 +27,024	+39%	+$1.22M	0.79%	26
2022 Q1	$4.26M	Hold	68,624	–	–	0.53%	26
2021 Q4	$4.84M	Sell	68,624 -5,000	-7%	-$356K	0.64%	23
2021 Q3	$5.14M	Sell	73,624 -878	-1%	-$69.9K	0.73%	27
2021 Q2	$6.21M	Sell	74,502 -13,677	-16%	-$968K	0.7%	24
2021 Q1	$4.82M	Hold	88,179	–	–	0.69%	26
2020 Q4	$3.78M	Hold	88,179	–	–	0.65%	23
2020 Q3	$2.65M	Buy	88,179 +6,374	+8%	+$214K	0.53%	26
2020 Q2	$2.54M	Buy	+81,805	New	+$2.2M	0.54%	29

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Archon Capital Management's HBIO Position: Q2 2024 in Review

Archon Capital Management sold out of Harvard Bioscience (HBIO) in Q2 2024, closing a stake of 26,086 shares — an estimated $1.11M sold.

Archon Capital Management first reported a position in HBIO in Q2 2020 and held it in 16 quarters. The position peaked at $6.21M in Q2 2021. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

Archon Capital Management reported no remaining Harvard Bioscience position as of Q2 2024 after selling out during the quarter.
Archon Capital Management sold 26,086 Harvard Bioscience shares in Q2 2024, an estimated $1.11M.
Archon Capital Management first reported a position in Harvard Bioscience in Q2 2020 and held it in 16 quarters.
Archon Capital Management's Harvard Bioscience position peaked at $6.21M in Q2 2021.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on Archon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.